Ignite Creation Date:
2025-12-24 @ 4:03 PM
Ignite Modification Date:
2026-02-24 @ 5:09 AM
Study NCT ID:
NCT00391066
Status:
TERMINATED
Last Update Posted:
2015-10-02
First Post:
2006-10-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Sponsor:
Biogen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
152CL201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None